DOP2016000311A - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
DOP2016000311A
DOP2016000311A DO2016000311A DO2016000311A DOP2016000311A DO P2016000311 A DOP2016000311 A DO P2016000311A DO 2016000311 A DO2016000311 A DO 2016000311A DO 2016000311 A DO2016000311 A DO 2016000311A DO P2016000311 A DOP2016000311 A DO P2016000311A
Authority
DO
Dominican Republic
Prior art keywords
new compounds
rory
retinoid
treatment
relates
Prior art date
Application number
DO2016000311A
Other languages
English (en)
Inventor
Robert W Marquis Jr
Hui Lei
Xin Ma
Feng Ren
Xichen Lin
Original Assignee
Glaxomithkline Intellectual Property Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxomithkline Intellectual Property Dev Ltd filed Critical Glaxomithkline Intellectual Property Dev Ltd
Publication of DOP2016000311A publication Critical patent/DOP2016000311A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a nuevos moduladores del receptor gamma huérfano relacionado con retinoide (RORy) y a su uso en el tratamiento de enfermedades mediadas por el RORy.
DO2016000311A 2014-05-28 2016-11-28 Nuevos compuestos DOP2016000311A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2014078701 2014-05-28

Publications (1)

Publication Number Publication Date
DOP2016000311A true DOP2016000311A (es) 2017-02-28

Family

ID=54698095

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000311A DOP2016000311A (es) 2014-05-28 2016-11-28 Nuevos compuestos

Country Status (18)

Country Link
US (1) US9868724B2 (es)
EP (1) EP3148987B1 (es)
JP (1) JP6522665B2 (es)
KR (1) KR20170008852A (es)
CN (1) CN107001342B (es)
AU (1) AU2015267911B2 (es)
CA (1) CA2953637C (es)
CL (1) CL2016003023A1 (es)
CR (1) CR20160549A (es)
DO (1) DOP2016000311A (es)
EA (1) EA032272B1 (es)
ES (1) ES2716966T3 (es)
IL (1) IL248983A0 (es)
MX (1) MX2016015631A (es)
PE (1) PE20170137A1 (es)
PH (1) PH12016502331A1 (es)
SG (1) SG11201609722UA (es)
WO (1) WO2015180614A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013354109B2 (en) 2012-12-06 2016-06-16 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases
AU2015267910B2 (en) 2014-05-28 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Novel compounds
BR112016027732B1 (pt) 2014-05-28 2023-11-07 Glaxosmithkline Intellectual Property Development Limited Composto modulador do receptor gama, composição farmacêutica que compreende o referido composto, bem como uso do mesmo para o tratamento de doenças inflamatórias e autoimunes mediadas por rory
EA032272B1 (ru) 2014-05-28 2019-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новые соединения
UA123330C2 (uk) 2016-07-13 2021-03-17 Лео Фарма А/С Гетероароматичні модулятори ретинол-зв'язаного орфанного рецептора гамма
CN109134476B (zh) * 2017-06-15 2021-03-19 复旦大学 桥环哌嗪类衍生物或其盐及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012145254A2 (en) 2011-04-16 2012-10-26 Board Of Regents, The University Of Texas System Methods of using inhibitors of rorϒt to treat disease
US8604069B2 (en) 2011-04-28 2013-12-10 Japan Tobacco Inc. Amide compound and medicinal use thereof
US9586928B2 (en) * 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
JP2014528933A (ja) 2011-09-09 2014-10-30 ニューヨーク ユニバーシティ ＲＯＲγｔモジュレーターとしてのアミド化合物およびその使用
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
WO2013100027A1 (ja) * 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物
AU2013254657B2 (en) 2012-04-27 2015-12-24 Glaxo Group Limited Novel compounds
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
JO3215B1 (ar) * 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
RS56283B1 (sr) * 2012-10-16 2017-12-29 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
AU2013354109B2 (en) * 2012-12-06 2016-06-16 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
US20160257664A1 (en) 2013-10-25 2016-09-08 Glaxosmithkline Llc Novel compounds
WO2015061686A2 (en) 2013-10-25 2015-04-30 St. Jude Children's Research Hospital, Inc. Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer
EA032272B1 (ru) 2014-05-28 2019-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новые соединения
BR112016027732B1 (pt) 2014-05-28 2023-11-07 Glaxosmithkline Intellectual Property Development Limited Composto modulador do receptor gama, composição farmacêutica que compreende o referido composto, bem como uso do mesmo para o tratamento de doenças inflamatórias e autoimunes mediadas por rory
AU2015267910B2 (en) 2014-05-28 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Novel compounds

Also Published As

Publication number Publication date
IL248983A0 (en) 2017-01-31
AU2015267911B2 (en) 2017-10-26
PE20170137A1 (es) 2017-03-05
EA201692395A1 (ru) 2017-03-31
ES2716966T3 (es) 2019-06-18
JP2017519738A (ja) 2017-07-20
KR20170008852A (ko) 2017-01-24
EP3148987A1 (en) 2017-04-05
CL2016003023A1 (es) 2017-04-21
PH12016502331A1 (en) 2017-02-06
WO2015180614A1 (en) 2015-12-03
CA2953637A1 (en) 2015-12-03
CN107001342A (zh) 2017-08-01
EP3148987A4 (en) 2017-11-15
US9868724B2 (en) 2018-01-16
US20170101399A1 (en) 2017-04-13
SG11201609722UA (en) 2016-12-29
CR20160549A (es) 2017-04-28
EP3148987B1 (en) 2019-01-02
AU2015267911A1 (en) 2016-12-01
MX2016015631A (es) 2017-04-25
CN107001342B (zh) 2020-02-07
EA032272B1 (ru) 2019-05-31
CA2953637C (en) 2022-11-29
JP6522665B2 (ja) 2019-05-29

Similar Documents

Publication Publication Date Title
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CR20150302A (es) Moduladores del receptor huérfano gamma relacionado a retinoide (ror-gamma) para uso en el tratamiento de enfermedades autoinmunes e inflamatorias
DOP2016000311A (es) Nuevos compuestos
MX2016015630A (es) Nuevos compuestos.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
UY36311A (es) Indazoles sustituidos con bencilo
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
NI201700019A (es) Anticuerpos anti tigit
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CR20140493A (es) Compuestos novedosos
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
EA201691582A1 (ru) Новые фармацевтические препараты
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
AR102712A1 (es) Agonistas parciales del receptor de insulina
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
ECSP17015977A (es) Terapia de combinacion
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
NZ727456A (en) Fused triterpene compounds and uses thereof
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
GT201600255A (es) Compuestos, composición farmacéutica y su uso para tratar enfermedades neurodegenerativas
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
UY36398A (es) NUEVOS MODULADORES DEL RECEPTOR GAMMA HUERFANO RELACIONADO CON RETINOIDE (RORy)